188Re-octreotide

188Re-octreotide is a radiolabeled peptide drug that consists of the somatostatin analog octreotide conjugated to the beta-emitting radioisotope rhenium-188. It is designed for targeted radionuclide therapy, primarily for the treatment of neuroendocrine tumors and other tumors expressing somatostatin receptors. Octreotide binds to somatostatin receptors (mainly SSTR2) that are highly expressed on certain tumors; the attached rhenium-188 delivers cytotoxic radiation directly to these cells, inducing cell death through DNA damage. 188Re-octreotide is typically used in experimental or compassionate settings for patients with inoperable or metastatic neuroendocrine tumors.

Other names

rhenium-188 octreotiderhenium188 octreotiderhenium 188 octreotideRe-188-octreotideRe188-octreotideRe 188-octreotide